Q32 Bio announced positive 36-week topline results from Part B of the Phase 2 SIGNAL-AA trial in severe-to-very-severe AA, and said it plans to advance bempikibart into a registration-directed program in the first half of 2027; the drug has FDA Fast Track designation.
- Lab
- Phase 1
- Phase 2
- Phase 3
- Approved
Phase 2
How it works
Fully human anti-IL-7 receptor-alpha monoclonal antibody that blocks IL-7 and TSLP signalling to re-regulate the adaptive immune cells attacking hair follicles.
Results so far
Specific numeric efficacy figures for the 36-week Part B readout were not captured in the search snippets reviewed — flagged as needing direct verification from the primary press release before quoting numbers.
What's next
Registration-directed (pivotal) program targeted to begin H1 2027.
In India
No India-specific development identified.
Sources
- News report ↗ (accessed 2026-10-17)
- Regulator ↗ (accessed 2026-10-17)
- Company announcement ↗ (accessed 2026-10-17)
- Trial registry ↗ (accessed 2026-10-17)
What to do today: treatments in development aren't a reason to wait. Ask a dermatologist about the options that work now, such as minoxidil, or see alopecia areata treatments.
Discussion
Share your experience or ask a question. New members' posts are reviewed before they appear.